Beta-2-adrenoceptor agonists as inhibitors of lung vascular permeability to radiolabelled transferrin in the adult respiratory distress syndrome in man.
Increased lung vascular permeability leading to increased plasma protein extravasation and accumulation (PPA) is a characteristic feature of acute lung injury. Using a previously described technique, PPA was monitored in the lungs of patients with the adult respiratory distress syndrome (ARDS)--an extreme example of acute lung injury in man. An external radiation probe detector was used to monitor the pulmonary accumulation of the plasma protein transferrin radiolabelled in-vivo with 113mIn. Ten patients with ARDS exhibiting increased PPA indices (greater than 1.0 x 10(-3)/min) were given an intravenous infusion of terbutaline (7 micrograms/kg) over 30 min. Of the four patients in whom the post-drug PPA indices remained within the ARDS range, none survived, whilst five of the six patients in whom the post-drug PPA indices were reduced to below 1.0 x 10(-3)/min survived. PPA indices prior to the administration of terbutaline were not significantly different between the survivor (n = 5) and non-survivor (n = 5) groups. There was a significant decrease in the PPA indices following terbutaline in survivors (p less than 0.01) but not in non-survivors. Thus beta-2-agonists in therapeutic doses can inhibit increased lung vascular permeability in man. These findings may have prognostic and therapeutic implications for beta-2-agonists in ARDS.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D002199:Capillary Permeability / Q000187:drug effects*; D006801:Humans; D007204:Indium; D008168:Lung / Q000000981:diagnostic imaging*; D011868:Radioisotopes; D011877:Radionuclide Imaging; D012128:Respiratory Distress Syndrome / Q000000981:diagnostic imaging* / Q000188:drug therapy; D013726:Terbutaline / Q000627:therapeutic use*; D014168:Transferrin
D000318:Adrenergic beta-Agonists; D011868:Radioisotopes; D014168:Transferrin; D007204:Indium; D013726:Terbutaline